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After the publication of this work [1], a few points were
brought to our attention:
The clinical data of patient 2 are incorrect. A revised
version of Table 1 [1] showing the corrected patient
characteristics is presented here. Consequently, the
description of the patient cohort in the Materials and
Methods section is incorrect. The correct description is:
“Plasma miRNA analysis was performed on 18 HNSCC
patients treated with local X-ray-irradiation using a
linear accelerator […].
17 out of 18 patients received concurrent chemotherapy
(13 patients received 5-fluorouracil (5-FU) plus
mitomycin C (MMC) [21], 3 patients MMC and 1
patient cisplatin weekly)”.
There is a typing error in the Results section [1]
concerning the p value of the up-regulation of miR-425-5p.
The correct sentence is:
“The qRTPCR assays confirmed an up-regulation of
miR-425-5p with a p value close to the significance level
(p = 0.052) […]”.
The corrections do not affect any results or conclusions
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Table 1 Patient characteristics




Median age, years 57.5
























(in addition to radiotherapy)
5-FU +MMC 13 (patient 2, 3, 5–7, 9–13, 15–17)
MMC 3 (patient 1, 14, 18)
Cisplatin 1 (patient 8)





5-FU = 5-fluorouracil; MMC =mitomycin C; n.a. = not available.
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